Markov Aleksandr, Pokhrel Akriti, Wang Jen Chin
Division of Internal Medicine, Brookdale University Hospital Medical Center, Brooklyn, NY 11201, USA.
Division of Hematology and Oncology, Brookdale University Hospital Medical Center, Brooklyn, NY 11201, USA.
Biomedicines. 2025 Jun 11;13(6):1437. doi: 10.3390/biomedicines13061437.
Poorly differentiated neuroendocrine tumors of the pancreas (pd-PNETs) are very rare tumors. Differentiating primary pd-PNET from neuroendocrine carcinomas, which metastasize to the pancreas, can be difficult. We will refer to any neuroendocrine carcinoma with pancreatic metastasis as secondary pd-PNETs. This study evaluates the differences in incidence, clinical picture, outcomes, and treatment between primary and secondary pd-PNETs. A comprehensive search of the pd-PNET database was performed to gather data on incidence, race, age, gender, clinical picture, and outcomes for primary and secondary pd-PNETs. The emphasis was on small-cell lung cancer (SCLC) and Merkel cell carcinoma (MCC) due to their associations with secondary pd-PNET. Additional data from the PubMed database were analyzed, and 12 case reports of primary pd-PNETs were added for clinical characteristic analysis. Primary and secondary pd-PNETs exhibit highly similar profiles in terms of age, gender, race, and clinical features. However, treatment strategies are significantly different. Primary pd-PNETs are managed with tumor resection and platinum-based chemotherapy. Primary tumors usually have poor prognosis, with a median survival of 12 months. Treatment for secondary pd-PNETs varies based on the primary tumor. The treatment strategy for metastatic MCC was changed to immune checkpoint inhibitors (ICIs), and survival improved. Tarlatamab also recently showed a good response in the management of SCLC. These findings highlight the need for accurate and timely diagnosis to provide correct treatment. Patients with primary and secondary pd-PNETs exhibit similar clinical presentations and epidemiological characteristics. However, when a poorly differentiated neuroendocrine pancreatic mass is identified, it is critical to exclude MCC or small-cell lung carcinoma metastasis, as treatments may be different and prognosis may also be different.
胰腺低分化神经内分泌肿瘤(pd-PNETs)是非常罕见的肿瘤。将原发性pd-PNET与转移至胰腺的神经内分泌癌区分开来可能具有挑战性。我们将任何伴有胰腺转移的神经内分泌癌称为继发性pd-PNETs。本研究评估原发性和继发性pd-PNETs在发病率、临床表现、预后及治疗方面的差异。对pd-PNET数据库进行了全面检索,以收集原发性和继发性pd-PNETs的发病率、种族、年龄、性别、临床表现及预后数据。由于小细胞肺癌(SCLC)和默克尔细胞癌(MCC)与继发性pd-PNET相关,因此重点关注这两种癌症。分析了来自PubMed数据库的其他数据,并增加了12例原发性pd-PNETs的病例报告用于临床特征分析。原发性和继发性pd-PNETs在年龄、性别、种族和临床特征方面表现出高度相似的特征。然而,治疗策略存在显著差异。原发性pd-PNETs采用肿瘤切除术和铂类化疗进行治疗。原发性肿瘤通常预后较差,中位生存期为12个月。继发性pd-PNETs的治疗因原发性肿瘤而异。转移性MCC的治疗策略改为免疫检查点抑制剂(ICIs),生存期有所改善。Tarlatamab最近在SCLC的治疗中也显示出良好的疗效。这些发现凸显了准确及时诊断以提供正确治疗的必要性。原发性和继发性pd-PNETs患者表现出相似的临床表现和流行病学特征。然而,当发现胰腺低分化神经内分泌肿块时,排除MCC或小细胞肺癌转移至关重要,因为治疗方法可能不同,预后也可能不同。